Company Encyclopedia
View More
name
Achilles Therapeutics
ACHL.US
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
1.875 T
ACHL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Achilles Therapeutics to delist ADSs from Nasdaq and deregister from SEC, calling for liquidation with General Meeting on March 20, 2025.

    On February 28, 2025, Achilles Therapeutics plc (NASDAQ: ACHL) announced its decision to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister the ADSs from the SEC under Section 12(b) of the Exchange Act. The company will hold a General Meeting on March 20, 2025, to seek shareholder approval for starting a members’ voluntary liquidation. This delisting is part of the process related to the planned liquidation.

    Unusual Whales·
    US
    ACHL
    0.00%
    Unusual Whales·
    US
    ACHL
    0.00%

    Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation

    Syncona's board has decided that its portfolio company, Achilles Therapeutics, will pursue a members' solvent voluntary liquidation to return capital to shareholders. Shareholders are expected to receive between 1.20 and 1.32 pounds per share, pending approval at a general meeting on March 20. Syncona holds 11,086,909 American depositary shares in Achilles, valued at 8.5 million pounds as of September 30, 2024.

    Trading View·
    US
    ACHL
    0.00%
    Trading View·
    US
    ACHL
    0.00%

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    In Tuesday's pre-market session, Evaxion Biotech (EVAX) shares surged 92.1% to $4.61, while Anitra (AZTR) rose 55.15% to $0.43. Other gainers included Kairos Pharma (KAPA) up 25.65% to $1.91, and Achilles Therapeutics (ACHL) up 20.53% to $1.35. Conversely, Universe Pharmaceuticals (UPC) shares fell 23.3% to $0.32, with Foghorn Therapeutics (FHTX) down 19.35% to $3.21. HCW Biologics (HCWB) and ImmuCell (ICCC) also saw declines of 18.23% and 12.36%, respectively.

    Benzinga·
    US
    ACHL
    0.00%
    US
    UPC
    -2.86%
    Benzinga·
    US
    ACHL
    0.00%
    US
    UPC
    -2.86%

    Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts

    Syncona's investment, Achilles Therapeutics, has sold technology assets to AstraZeneca, including a commercial license for data and samples from the TRACERx non-small cell lung cancer study. AstraZeneca will pay $12 million and become the sponsor of Achilles' Material Acquisition Platform. Achilles plans to reduce its employee headcount and Board size as part of this transition.

    rttnews·
    US
    AZN
    +2.62%
    US
    ACHL
    0.00%
    rttnews·
    US
    AZN
    +2.62%
    US
    ACHL
    0.00%

    Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

    Achilles Therapeutics has announced a $12 million deal with AstraZeneca for the transfer of TRACERx data and tumor samples, following a strategic review. The company plans to cut jobs and reduce its Board of Directors while remaining compliant with Nasdaq and SEC requirements. The TRACERx study, which has collected extensive genetic data from lung cancer patients, will aid in developing improved cancer therapies. Following the announcement, ACHL shares rose by 7.01% to $1.050.

    Benzinga·
    US
    ACHL
    0.00%
    US
    AZN
    +2.62%
    UK
    AZN
    0.00%
    Benzinga·
    US
    ACHL
    0.00%
    US
    AZN
    +2.62%
    UK
    AZN
    0.00%